AnaptysBio, Inc. (NASDAQ:ANAB) Receives $41.45 Average Price Target from Brokerages

AnaptysBio, Inc. (NASDAQ:ANAB) has been given an average recommendation of “Moderate Buy” by the twelve analysts that are presently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $41.45.

Several research analysts have commented on the stock. Wedbush restated an “outperform” rating and issued a $40.00 price objective (down from $42.00) on shares of AnaptysBio in a report on Wednesday, December 11th. Guggenheim lowered their price objective on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, December 12th. Wells Fargo & Company cut their price objective on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a research report on Thursday, December 12th. Truist Financial decreased their target price on AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. dropped their price target on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a research report on Thursday, December 19th.

AnaptysBio Price Performance

NASDAQ ANAB opened at $14.21 on Monday. AnaptysBio has a 1 year low of $12.51 and a 1 year high of $41.31. The stock has a market capitalization of $432.40 million, a PE ratio of -2.34 and a beta of -0.02. The business’s 50-day moving average is $18.67 and its 200 day moving average is $28.19.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. The firm had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. As a group, equities research analysts anticipate that AnaptysBio will post -6.02 earnings per share for the current year.

Insider Buying and Selling at AnaptysBio

In other news, Director Ecor1 Capital, Llc bought 6,646 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were purchased at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the purchase, the director now owns 7,880,094 shares in the company, valued at approximately $102,047,217.30. This represents a 0.08 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 33.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On AnaptysBio

A number of hedge funds have recently added to or reduced their stakes in ANAB. Rhumbline Advisers boosted its stake in AnaptysBio by 1.8% during the 2nd quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company’s stock valued at $745,000 after purchasing an additional 525 shares during the last quarter. Algert Global LLC lifted its holdings in shares of AnaptysBio by 11.8% during the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock valued at $255,000 after purchasing an additional 1,078 shares in the last quarter. nVerses Capital LLC boosted its position in shares of AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 1,400 shares during the last quarter. Values First Advisors Inc. bought a new stake in AnaptysBio in the 3rd quarter worth about $49,000. Finally, China Universal Asset Management Co. Ltd. raised its position in AnaptysBio by 81.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock worth $195,000 after buying an additional 2,600 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.